3
Participants
Start Date
October 22, 2021
Primary Completion Date
June 1, 2023
Study Completion Date
June 1, 2023
Dapagliflozin 10Mg Tab
This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
Placebo
This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
University of Pennsylvania, Philadelphia
Collaborators (1)
Amgen
INDUSTRY
University of Pennsylvania
OTHER